Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + cytarabine + mitoxantrone + filgrastim
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
CLAG-M is a multi-agent chemotherapy regimen composed of cladribine, cytarabine (also known as Ara-C), mitoxantrone, and filgrastim (G-CSF). It is primarily used for the treatment of acute myeloid leukemia (AML), especially in relapsed or refractory cases. Cladribine is a purine analog that inhibits DNA synthesis; cytarabine is an antimetabolite that interferes with DNA replication; mitoxantrone is an anthracenedione that intercalates into DNA and inhibits topoisomerase II; and filgrastim is a granulocyte colony-stimulating factor used to stimulate white blood cell production. The combination aims to maximize anti-leukemic activity while supporting hematopoietic recovery with G-CSF[1][2][4][5].
- Other names
- cladribine, cytarabine, filgrastim, and mitoxantroneCLAG-M regimen
02
Targets
TOP2A (DNA topoisomerase II)DNA polymerase familyCSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on cladribine + cytarabine + mitoxantrone + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + cytarabine + mitoxantrone + filgrastim.